文献速递血栓与止血

无诱因静脉血栓栓塞后抗磷脂综合征的患病率与结局:多中心真实世界数据分析

Prevalence and outcomes of antiphospholipid syndrome after unprovoked venous thromboembolism: a multicenter real-world data analysis.
PubMed 文献 · J Thromb Haemost · 2026-05-12

该多中心回顾性分析纳入英国5中心897例无诱因VTE患者,总体APS患病率为11.7%,全面筛查组高于选择性筛查组(15.8% vs 5.8%)。

要点

  • 无诱因VTE后APS总体患病率为11.7%,全面筛查组为15.8%,选择性筛查组为5.8%。
  • 基线临床特征对APS预测价值有限。
  • APS患者年血栓复发率为2.1/100人年,抗凝药类型间差异无统计学意义。

核心结论

  • 无诱因VTE后APS患病率值得关注,选择性筛查在实际中识别出更少的APS病例。
  • 在无诱因VTE患者中识别aPL可能有助于讨论抗凝疗程和药物选择,但最佳筛查策略需进一步前瞻性评估。

研究设计与样本

  • 回顾性多中心真实世界分析,纳入英国5个中心的897例无诱因VTE患者。
  • 1个中心采用全面aPL筛查(n=533),4个中心采用选择性筛查(n=364)。
  • 主要结局为APS患病率,次要结局包括按筛查策略和按抗凝药类型(DOAC vs VKA)分层的无血栓生存率。

主要发现

  • 总体APS患病率为11.7%,全面筛查组高于选择性筛查组(15.8% vs 5.8%)。
  • 基线临床特征对APS的预测能力较差。
  • 105例APS患者(中位随访4.2年)年血栓复发率为2.1/100人年。

关键数值与推荐

  • APS总体患病率11.7%(897例无诱因VTE患者)。
  • 全面筛查组APS患病率15.8%(n=533),选择性筛查组5.8%(n=364)。
  • APS患者年血栓复发率2.1/100人年(105例,中位随访4.2年)。

临床怎么用

  • 对无诱因VTE患者应考虑进行aPL检测以识别APS,从而个体化讨论抗凝疗程和药物选择。
  • 选择性筛查可能漏诊部分APS病例,临床需权衡全面筛查的获益与成本。
  • APS患者抗凝药物选择(DOAC vs VKA)需结合复发风险个体化评估,目前证据未显示显著差异。

局限性

  • 回顾性设计,筛查策略非随机分配,存在选择偏倚可能。
  • APS患者样本量有限(105例),DOAC与VKA比较的统计效能不足。
  • 基线临床特征对APS预测价值有限,可能影响筛查策略的推广。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Guidance for antiphospholipid antibody (aPL) testing after unprovoked venous thromboembolism (VTE) is inconsistent. Real-world data on the prevalence and outcomes of antiphospholipid syndrome (APS) in those presenting with unprovoked VTE are limited. OBJECTIVES: This study determined APS prevalence after unprovoked VTE, compared outcomes from universal vs selective aPL testing, and assessed thrombosis recurrence in patients with APS within a multicenter UK cohort. METHODS: This retrospective analysis included 897 patients with unprovoked VTE from 5 UK centers. One center used universal (n = 533) and 4 used selective (n = 364) aPL testing. The primary outcome was APS prevalence. Secondary outcomes included thrombosis-free survival by testing strategy and by anticoagulant (direct oral anticoagulants vs vitamin K antagonists) in patients with APS. RESULTS: The overall APS prevalence was 11.7% and was higher in the universal testing than in the selective cohort (15.8% vs 5.8%). Baseline clinical features were poor predictors of APS. Among 105 patients with APS (median follow-up, 4.2 years), the annual thrombotic recurrence rate was 2.1 per 100 person-years. A nonsignificant trend toward higher recurrence was observed over time for direct oral anticoagulants vs vitamin K antagonists (3.8 vs 1.3 events/100 person-years; P = .16). No thrombosis-free survival difference was found between testing strategies (P = .71). CONCLUSION: The prevalence of APS following unprovoked VTE is notable, and selective testing identified fewer APS cases in practice. Identifying aPLs in patients with unprovoked VTE may inform discussions regarding anticoagulation duration and choice, although optimal testing strategies require further prospective evaluation.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Mathur A, Cox C, Banerjee S, et al. Prevalence and outcomes of antiphospholipid syndrome after unprovoked venous thromboembolism: a multicenter real-world data analysis. J Thromb Haemost. 2026. PMID: 42128060. doi:10.1016/j.jtha.2026.04.036

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。